US6040347A - Treatment of seborrhoea/cutaneous disorders with octoxyglycerol - Google Patents

Treatment of seborrhoea/cutaneous disorders with octoxyglycerol Download PDF

Info

Publication number
US6040347A
US6040347A US09/101,623 US10162398A US6040347A US 6040347 A US6040347 A US 6040347A US 10162398 A US10162398 A US 10162398A US 6040347 A US6040347 A US 6040347A
Authority
US
United States
Prior art keywords
composition
octoxyglycerol
group
agents
aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US09/101,623
Other languages
English (en)
Inventor
Sylvie Cupferman
Jean-Pierre Laugier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Assigned to L'OREAL reassignment L'OREAL ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CUPFERMAN, SYLVIE, LAUGIER, JEAN-PIERRE
Application granted granted Critical
Publication of US6040347A publication Critical patent/US6040347A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/008—Preparations for oily hair

Definitions

  • the subject-matter of the present invention is the use of octoxyglycerol in a cosmetic or dermatological composition for treating seborrhoea and cutaneous disorders which are associated with it, in particular acne and/or hyperseborrhoea.
  • the secretion of sebum is a normal phenomenon and useful to the skin and the hair.
  • the hypersecretion of sebum known as seborrhoea
  • seborrhoea is annoying and sometimes results in a cutaneous pathology, in particular a greasy skin and even one suffering from acne, and a seborrhoeic condition of the scalp.
  • the consequences of the sebaceous hypersecretion and the disturbance of the keratinization of the pilo-sebaceous follicle is that the pilo-sebaceous follicle becomes blocked and that retentional lesions or comedones are formed.
  • pathologies and in particular acne and/or hyperseborrhoea relate in particular to the colonization of the skin or hair follicle by microorganisms of the genus Propionibacterium, such as Propionibacterium acnes, Propionibacterium granulosum or Propionibacterium avidum.
  • triclosan exhibits a not insignificant toxicity, even by the topical route.
  • it has proved to be insufficiently effective, in particular in certain vehicles where its activity is inhibited by the surfactants.
  • Hexamidine and hexetidine in the form of salts, are sensitizing substances capable of causing allergies.
  • benzalkonium chloride can prove to be irritating at the normal doses of use. Moreover it destabilizes compositions containing anionic surfactants.
  • the subject-matter of the present invention is precisely the use of specific compounds which make it possible to obtain this effect.
  • octoxyglycerol exhibited high activity with respect to Propionibacterium acnes and Propionibacterium granulosum and could thus be used in a cosmetic or dermatological composition as anti-seborrhoeic and anti-acne active agent.
  • the document DE-A-4,140,474 certainly describes the use of monoalkyl ethers of glycerol in compositions for cleansing and caring for the skin.
  • these compounds are used as supergreasing additives which prevent the drying of the skin in alcohol-based antiseptic and disinfectant compositions, the monoalkyl ethers of glycerol reinforcing the antiseptic effect of the alcohol while preventing the drying of the skin.
  • monoalkyl ethers of glycerol, particularly of octoxyglycerol to act against pathologies related to Propionibacterium acnes and Propionibacterium granulosum, and in particular to treat seborrhoea and acne, has never been described.
  • the document WO 93/25208 describes the use of monoalkyl ethers of glycerol in cytocidal, antibacterial and spermicidal compositions. This document does not specifically describe the activity of the monoalkyl ethers with respect to microorganisms of the genus Propionibacterium and still less pathologies related to Propionibacterium acnes and Propionibacterium granulosum and in particular seborrhoea and acne. Moreover, octoxyglycerol is not cited in this document.
  • the subject-matter of the present invention is thus the use of octoxyglycerol in a cosmetic composition for treating seborrhoea of the skin and/or of the scalp and/or cutaneous disorders associated with seborrhoea.
  • Another subject-matter of the present invention is the use of octoxyglycerol in the manufacture of a medicament intended to treat seborrhoea of the skin and/or of the scalp and/or cutaneous disorders associated with seborrhoea.
  • the cutaneous disorders associated with seborrhoea can in particular be acne or greasy skin with a tendency towards acne and/or hyperseborrhoea.
  • a further subject-matter of the present invention is consequently the use of octoxyglycerol in a cosmetic composition for treating acne and/or greasy skin with a tendency towards acne and/or hyperseborrhoea.
  • a further subject-matter of the present invention is the use of octoxyglycerol in the manufacture of a medicament intended to treat acne and/or greasy skin with a tendency towards acne and/or hyperseborrhoea.
  • a further subject-matter of the present invention is the use of octoxyglycerol in a cosmetic composition for acting against microorganisms of the genus Propionibacterium.
  • a further subject-matter of the present invention is the use of octoxyglycerol in the manufacture of a medicament intended to act against microorganisms of the genus Propionibacterium.
  • Another subject-matter of the present invention is a process for the cosmetic treatment of seborrhoea and/or of disorders associated with seborrhoea which consists in applying a composition containing at least octoxyglycerol on the skin and/or the scalp exhibiting disorders of seborrhoea.
  • Another subject-matter of the present invention is a process for the cosmetic treatment of acne, which consists in applying, on skin suffering from acne, a composition containing at least octoxyglycerol.
  • a final subject-matter of the invention is an anti-acne cosmetic and/or dermatological composition, characterized in that it comprises, in a cosmetically and/or dermatologically acceptable medium, at least an effective amount of octoxyglycerol as anti-acne active agent.
  • Octoxyglycerol (2-ethylhexyl 1-glyceryl ether) corresponds to the following formula (I):
  • R represents a 2-ethylhexyl radical
  • Octoxyglycerol is used, according to the present invention, in an amount preferably ranging from 0.05 to 10%, better still from 0.1 to 5% and yet better still from 0.1 to 2.5% of the total weight of the composition.
  • compositions according to the invention comprise a cosmetically and/or dermatologically acceptable medium, that is to say compatible with the skin, the mucous membranes, the hair and the scalp. They can be provided in all the pharmaceutical dosage forms appropriate for topical application, in particular in the form of aqueous, aqueous/alcoholic or oily solutions, of aqueous, aqueous/alcoholic or oily gels, of solid or pasty anhydrous products, of emulsions obtained by dispersion of a fatty phase in an aqueous phase (O/W) or vice versa (W/O), of suspensions, of microemulsions, of microcapsules, of microparticles or of vesicular dispersions of ionic type (liposomes) and/or non-ionic type.
  • These compositions are prepared according to the usual methods in the fields under consideration.
  • compositions according to the invention can also be used in the form of foams or in the form of aerosol compositions also comprising a pressurized propellent.
  • compositions according to the invention are those conventionally used in the fields under consideration.
  • compositions constitute in particular skin products, such as cleansing or treatment gels or creams, purifying lotions or milks, concealing sticks, anti-seborrhoeic shampoos or hair lotions, or compositions for combating hair loss for the scalp.
  • compositions of the invention can comprise the adjuvants conventionally employed in the fields under consideration, such as fatty substances, organic solvents, solubilizing agents, thickening and gelling agents, softeners, antioxidants, opacifying agents, stabilizing agents, foaming agents, fragrances, ionic or non-ionic emulsifiers, fillers, sequestering and chelating agents, preservatives, screening agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or any other ingredient commonly used in cosmetics.
  • adjuvants are introduced in the amounts generally used in the cosmetic or dermatological field and, for example, from 0 to 20% of the total weight of the composition.
  • the proportion of the fatty phase can range from 5 to 80% and preferably from 5 to 50% of the total weight of the composition.
  • the oils, the emulsifiers and the coemulsifiers used in the composition in the emulsion form are chosen from those conventionally used in the cosmetic or dermatological field.
  • the emulsifier and optionally the coemulsifier are present in the composition in a proportion ranging from 0.3 to 30% by weight and preferably from 0.5 to 20% by weight with respect to the total weight of the composition.
  • the emulsion can additionally contain lipid vesicles.
  • oils which can be used in the invention of mineral oils (isoparaffin), oils of vegetable origin (apricot kernel oil), oils of animal origin, synthetic oils, silicone oils (cyclopentadimethylsiloxane) and fluorinated oils.
  • Use can also be made, as fatty substances, of fatty alcohols, fatty acids (stearic acid) or waxes (carnauba wax, ozocerite).
  • emulsifiers which can be used in the invention, of, for example, ethylene glycol monostearate, sorbitan tristearate, the glycol palmitate-stearate/polyethylene glycol (6 EO) stearate/polyethylene glycol (32 EO) stearate mixture sold under the name "Tefose 63" by the company Gattefosse, and hydrogenated lecithin.
  • foaming agents of, for example, disodium N-carboxyethoxyethyl-N-(cocoylamidoethyl)aminoacetate, sodium lauryl ether sulphate, sodium lauroyl sarcosinate, triethanolamine lauryl sulphate and the mixture of sodium cocoyl isethionate and of coconut fatty acids.
  • acrylic copolymers such as the ethylene glycol dimethacrylate/lauryl methacrylate copolymer sold by the company Dow Corning under the name of Polytrap.
  • hydrophilic or lipophilic active agents of agents capable of complementing the effect of the alkyl ether of glycerol in the treatment of seborrhoea and of associated dermatoses and in particular of acne.
  • this agent is a keratolytic agent and in particular a ⁇ -hydroxyacid or a ⁇ -hydroxyacid.
  • the amount of agent can range, for example, from 0 to 20% and preferably from 0.05 to 5% of the total weight of the composition.
  • Mention may in particular be made, as ⁇ -hydroxyacids, of glycolic, lactic, malic, tartaric, citric and mandelic acids. Mention may be made, as ⁇ -hydroxyacids, of salicylic acid and its derivatives or 2-hydroxyalkanoic acids and their derivatives, such as 2-hydroxy-3-methylbenzoic acid and 2-hydroxy-3-methoxybenzoic acid.
  • hydrophilic active agents of, for example, proteins or protein hydrolysates, amino acids, polyols (glycerol or propylene glycol), urea, allantoin, sugars and sugar derivatives, vitamins, starch, or bacterial or plant extracts.
  • the composition comprising the alkyl ether appropriately comprises, in addition, at least one screening agent, so as to retain the effectiveness of the active agent according to the invention while protecting the skin from the harmful effects of solar radiation.
  • screening agents of organic screening agents or pigments which may or may not be in the form of nanoparticles (nanopigments).
  • organic screening agents are sulphone or sulphonate derivatives of benzophenone, sulphonic or sulphonate derivatives of benzylidenecamphor, and acrylates, such as octocrylene.
  • the amount of screening agent depends on the solar protection desired. It can range, for example, from 0 to 10% and preferably from 0.1 to 5% of the total weight of the composition.
  • the Elfacos GT 282S is dispersed in demineralized water at 80° C. and then the dispersion is cooled to 50° C. Furthermore, the foaming agents, the softening agent and the glycerol are dispersed at 50° C. in demineralized water with slow stirring and then this preparation is gently poured, with slow stirring, into the dispersion of Elfacos GT 282S. The octoxyglycerol is subsequently added thereto at 40° C.
  • the gel obtained is suitable for the treatment of seborrhoeic dermatitis, with application twice daily on the face.
  • the Elfan AT 84 G is dispersed in demineralized water at 80° C. After complete dissoluton, the hydrated magnesium aluminium silicate salt is added. The mixture is cooled to 60° C. and then the sodium lauroyl sarcosinate and the hydroxypropylmethylcellulose gel are added. The stearic acid and the ethylene glycol monostearate, which have been preheated on a water bath, are subsequently added. The octoxyglycerol and the fragrance are added to this mixture.
  • the cream obtained is suitable for the treatment of skin suffering from acne, by application twice daily on the face.
  • the mixture A containing the sorbitan tristearate, the emulsifier and the cyclopentadimethylsiloxane is prepared at 60° C.
  • the mixture B is prepared by swelling, in demineralized water at 70° C., the mixture of glycerol and of carbomer, followed by the xanthan gum.
  • the emulsion is prepared at 65° C. by pouring the mixture A into the mixture B with stirring. The combined mixture is allowed to cool to 50° C. and the Polytrap is added, followed by the octoxyglycerol.
  • the cream obtained is suitable for the treatment of the skin, by application once daily on the face and the back of the body.
  • the xanthan gum is swollen in demineralized water with the glycerol at 70° C. After cooling to 30° C., the glycolic acid, the ethyl alcohol, the co-solvent with the octoxyglycerol and the fragrance are added.
  • the gel obtained is suitable for the treatment of seborrhoeic skin, with application once to twice daily on the face.
  • the mixture of oxyethylenated (5 EO) soybean sterols and of hydrogenated lecithin is hydrated in demineralized water at 80° C. for 2 hours and this preparation is passed twice through a high-pressure homogenizer.
  • the apricot kernel oil and the cyclopentadimethylsiloxane are added thereto.
  • the mixture is passed through the high-pressure homogenizer and cooled to 30° C.
  • a dispersion of the fillers in the propylene glycol and the glycerol is prepared. This dispersion is dispersed in the mixture obtained above.
  • the Sepigel 305 and the octoxyglycerol are subsequently added.
  • the cream obtained is beige in colour and it is suitable for the treatment of the skin, by application twice daily on the face.
  • the oxides and the mould-release agent are dispersed in the mixture of waxes and of oil for 2 hours at 100° C.
  • the octoxyglycerol is added thereto immediately before casting.
  • the stick obtained can be applied on the face several times daily.
  • the glycerol, the ethyl alcohol, the cosolvent and the octoxyglycerol are mixed in the demineralized water.
  • the lotion obtained is suitable for cleansing the skin, by application twice daily on the face.
  • the carboxymethylcellulose is dispersed in the demineralized water, and the conditioning agent, the triethanolamine lauryl sulphate and the oxyethylenated methylglucose are added. After having cooled to 40° C., the octoxyglycerol is added.
  • the shampoo obtained is suitable for washing the hair and makes possible a marked improvement in the condition of the scalp.
  • the test described hereinbelow demonstrates the activity of octoxyglycerol with respect to Propionibacterium acnes and Propionibacterium granulosum.
  • Propionibacterium acnes and Propionibacterium granulosum are cultured on sloping tryptic soy broth agar.
  • Inoculation 4 ml of inoculum are introduced into the pill bottle and the pill bottle is placed in the incubator.
  • the colonies are then counted on the dishes containing more than 20 and less than 200 colonies.
  • compositions tested are as follows:
  • Decontamination is found, from 2 hours of contact, to be greater with Preparation A according to the invention.
  • the number of microorganisms is 1000 times less for Propionibacterium acnes and 10,000 times less for Propionibacterium granulosum than the inoculation level (T0), whereas, for Preparation B, it is unchanged.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US09/101,623 1996-11-15 1997-11-13 Treatment of seborrhoea/cutaneous disorders with octoxyglycerol Expired - Fee Related US6040347A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9613980 1996-11-15
FR9613980A FR2755852B1 (fr) 1996-11-15 1996-11-15 Utilisation d'un alkylether de glycerol dans une composition cosmetique et/ou dermatologique comme actif pour le traitement de la seborrhee et de l'acne
PCT/FR1997/002039 WO1998022081A1 (fr) 1996-11-15 1997-11-13 Utilisation de l'octoxyglycerine dans une composition cosmetique et/ou dermatologique comme actif pour le traitement de la seborrhee et/ou de l'acne

Publications (1)

Publication Number Publication Date
US6040347A true US6040347A (en) 2000-03-21

Family

ID=9497676

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/101,623 Expired - Fee Related US6040347A (en) 1996-11-15 1997-11-13 Treatment of seborrhoea/cutaneous disorders with octoxyglycerol

Country Status (9)

Country Link
US (1) US6040347A (ja)
EP (1) EP0892634B1 (ja)
JP (1) JP3553615B2 (ja)
KR (1) KR100283793B1 (ja)
CA (1) CA2241894C (ja)
DE (1) DE69716251T2 (ja)
ES (1) ES2185050T3 (ja)
FR (1) FR2755852B1 (ja)
WO (1) WO1998022081A1 (ja)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10025122A1 (de) * 2000-05-20 2001-11-22 Beiersdorf Ag Kombinationen von Clycerinmonoalkylethern und Fettsäreglyceriden
DE10025123A1 (de) * 2000-05-20 2001-11-22 Beiersdorf Ag Desodorierende Zubereitungenmit Mono- und Oligoglycerinmonocarbonsäuremonoestern, Arylverbindungen und Glycerylethern
DE10025124A1 (de) * 2000-05-20 2001-11-22 Beiersdorf Ag Kombinationen von Glycerinmo9noalkylethern und Aryl-substituierten Alkoholen
US6417146B1 (en) 1999-10-12 2002-07-09 Kao Corporation Aqueous liquid detergent compositions having a surfactant, fatty acid glycol ester and a glyceryl ether
US20030149097A1 (en) * 2000-06-09 2003-08-07 Wolfgang Beilfuss Storage-stable compositions of glycerol monoalkyl ethers
US20030152644A1 (en) * 2001-10-23 2003-08-14 Shanta Modak Gentle-acting skin-disinfectants
US20030187034A1 (en) * 2000-05-24 2003-10-02 Joachim Bunger Composition containing at least one aryl oxime and at least one active substance for treating acne and the use thereof
US20030232729A1 (en) * 2002-06-05 2003-12-18 Wolfgang Beilfuss Glyceryl ethers as preservatives for cooling lubricants
US20040102429A1 (en) * 2002-02-07 2004-05-27 Modak Shanta M. Zinc salt compositions for the prevention of dermal and mucosal irritation
US20040208908A1 (en) * 2003-04-16 2004-10-21 The Trustees Of Columbia University In The City Of New York Antimicrobial medical articles containing a synergistic combination of anti-infective compounds and octoxyglycerin
US20040258721A1 (en) * 2001-09-29 2004-12-23 Beiersdorf Ag Cosmetic or dermatological stick
US20050019431A1 (en) * 2003-07-17 2005-01-27 Modak Shanta M. Antimicrobial compositions containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof
US20050048139A1 (en) * 2002-02-07 2005-03-03 Modak Shanta M. Zinc salt compositions for the prevention of dermal and mucosal irritation
US20050124725A1 (en) * 1999-03-31 2005-06-09 Shanta Modak Triclosan and silver compound containing medical devices
US20050129639A1 (en) * 2003-11-07 2005-06-16 Eric Quemin Makeup composition comprising an emulsion
US20050220823A1 (en) * 2002-03-04 2005-10-06 Saunier Maggy B Ophthalmic composition comprising ascomycin
US20070020342A1 (en) * 2002-02-07 2007-01-25 Modak Shanta M Non-irritating compositions containing zinc salts
US20070092478A1 (en) * 2005-10-25 2007-04-26 Beiersdorf Ag Emulsion comprising 1,2-alkanediols and polar oil components
US20070190004A1 (en) * 2004-03-18 2007-08-16 Dirk Bockmuhl Substances with a probiotic action used in deodorants
US20070286767A1 (en) * 2006-06-08 2007-12-13 Burke Susan E Ophthalmic Compositions Comprising a Branched, Glycerol Monoalkyl Compound and a Fatty Acid Monoester
US20070287752A1 (en) * 2006-06-08 2007-12-13 Burke Susan E Ophthalmic Compositions Comprising A Branched, Glycerol Compound
US20080075761A1 (en) * 2000-12-22 2008-03-27 Modak Shanta M Antimicrobial Medical Devices Containing Chlorhexidine Free Base And Salt
US20080255015A1 (en) * 2007-04-16 2008-10-16 Air Liquide Sante (International) Composition based on glycerol ether/polyol mixtures
US20090035390A1 (en) * 2006-01-06 2009-02-05 Modak Shanta M Compositions containing zinc salts for coating medical articles
FR2923159A1 (fr) * 2007-11-07 2009-05-08 Oreal Utilisation d'un monoalkyle ether de glycerol a titre d'agent anti-oxydant
US20100278793A1 (en) * 2008-10-28 2010-11-04 L'oreal Treatment of greasy skin with a bacterial lystate
US9981069B2 (en) 2007-06-20 2018-05-29 The Trustees Of Columbia University In The City Of New York Bio-film resistant surfaces
US11730684B2 (en) * 2016-10-19 2023-08-22 Shiseido Company, Ltd. Cleansing composition

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1305365A (zh) * 1998-06-29 2001-07-25 宝洁公司 含二醇的免洗式发用组合物
US6221816B1 (en) * 1998-12-25 2001-04-24 Kao Corporation Detergent composition comprising a monoglyceryl ether
KR20030079231A (ko) * 2002-04-02 2003-10-10 지앤비코스메틱 피부 표면에 국소 적용되는, 피부 여드름 개선용 화장료조성물 및 그의 제조방법
DE10224979B4 (de) * 2002-06-05 2004-07-15 Schülke & Mayr GmbH Verwendung von synergistischen Zubereitungen auf Basis von Gemischen von Glycerinether mit aromatischem Alkohol zur Bekämpfung von Mykobakterien
DE102006062566A1 (de) 2006-12-29 2008-07-03 Henkel Kgaa Kosmetische und dermatologische Zusammensetzungen gegen unreine Haut und/oder Akne
JP7408329B2 (ja) * 2019-09-26 2024-01-05 株式会社Adeka セラミド合成促進剤
JP7498551B2 (ja) * 2019-09-26 2024-06-12 株式会社Adeka 抗炎症剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0025302A1 (en) * 1979-09-04 1981-03-18 Kao Corporation Alpha-mono(methyl-branched alkyl) glyceryl ether and a skin care cosmetic composition containing the same
DE4140474A1 (de) * 1991-12-09 1993-06-17 Schuelke & Mayr Gmbh Hautpflegeadditiv
WO1993025208A1 (en) * 1992-06-10 1993-12-23 Research Foundation For Mental Hygiene, Inc. Spermicidal and cytocidal fatty acid compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55160713A (en) * 1979-06-04 1980-12-13 Shiseido Co Ltd Stable aqueous powder dispersion composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0025302A1 (en) * 1979-09-04 1981-03-18 Kao Corporation Alpha-mono(methyl-branched alkyl) glyceryl ether and a skin care cosmetic composition containing the same
DE4140474A1 (de) * 1991-12-09 1993-06-17 Schuelke & Mayr Gmbh Hautpflegeadditiv
WO1993025208A1 (en) * 1992-06-10 1993-12-23 Research Foundation For Mental Hygiene, Inc. Spermicidal and cytocidal fatty acid compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Database WPI, Week 8108, Derwent Publications Ltd., London, GB; AN 81 1255ld, XP002036883, Stable aq. powder dispersion cosmetic obtd. by dispersing powder in gel obtd, by addn. of sucrose fatty acid ester, alpha monoglycerineether and surfactant to water , Dec. 13, 1980. *
Database WPI, Week 8108, Derwent Publications Ltd., London, GB; AN 81-1255ld, XP002036883, "Stable aq. powder dispersion cosmetic-obtd. by dispersing powder in gel obtd, by addn. of sucrose fatty acid ester, alpha monoglycerineether and surfactant to water", Dec. 13, 1980.

Cited By (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050124725A1 (en) * 1999-03-31 2005-06-09 Shanta Modak Triclosan and silver compound containing medical devices
US6417146B1 (en) 1999-10-12 2002-07-09 Kao Corporation Aqueous liquid detergent compositions having a surfactant, fatty acid glycol ester and a glyceryl ether
EP1157687A3 (de) * 2000-05-20 2002-08-14 Beiersdorf Aktiengesellschaft Kombinationen von Glycerinmonoalkylethern und Aryl-substituierten Alkoholen
EP1157685A2 (de) * 2000-05-20 2001-11-28 Beiersdorf AG Desodorierende Zubereitungen mit Mono- und Oligoglycerinmonocarbonsäuremonoestern, Arylverbindungen und Glycerylethern
EP1157687A2 (de) * 2000-05-20 2001-11-28 Beiersdorf Aktiengesellschaft Kombinationen von Glycerinmonoalkylethern und Aryl-substituierten Alkoholen
DE10025124A1 (de) * 2000-05-20 2001-11-22 Beiersdorf Ag Kombinationen von Glycerinmo9noalkylethern und Aryl-substituierten Alkoholen
DE10025123A1 (de) * 2000-05-20 2001-11-22 Beiersdorf Ag Desodorierende Zubereitungenmit Mono- und Oligoglycerinmonocarbonsäuremonoestern, Arylverbindungen und Glycerylethern
DE10025122A1 (de) * 2000-05-20 2001-11-22 Beiersdorf Ag Kombinationen von Clycerinmonoalkylethern und Fettsäreglyceriden
EP1157685A3 (de) * 2000-05-20 2003-11-26 Beiersdorf AG Desodorierende Zubereitungen mit Mono- und Oligoglycerinmonocarbonsäuremonoestern, Arylverbindungen und Glycerylethern
DE10025123B4 (de) * 2000-05-20 2014-07-10 Beiersdorf Ag Desodorierende Zubereitungen mit Oligoglycerinmonocarbonsäuremonoestern, Arylverbindungen und Glycerylethern
US20030187034A1 (en) * 2000-05-24 2003-10-02 Joachim Bunger Composition containing at least one aryl oxime and at least one active substance for treating acne and the use thereof
US20030149097A1 (en) * 2000-06-09 2003-08-07 Wolfgang Beilfuss Storage-stable compositions of glycerol monoalkyl ethers
US8592489B2 (en) 2000-06-09 2013-11-26 Air Liquide Sante (International) Storage-stable compositions of glycerol monoalkyl ethers
US6956062B2 (en) * 2000-06-09 2005-10-18 Air Liquide Santé (International) Storage-stable compositions of glycerol monoalkyl ethers
US8383143B2 (en) 2000-12-22 2013-02-26 The Trustees Of Columbia University In The City Of New York Antimicrobial medical devices containing chlorhexidine free base and salt
US8906401B2 (en) 2000-12-22 2014-12-09 The Trustees Of Columbia University In The City Of New York Antimicrobial medical devices containing chlorhexidine free base and salt
US20080075761A1 (en) * 2000-12-22 2008-03-27 Modak Shanta M Antimicrobial Medical Devices Containing Chlorhexidine Free Base And Salt
US8329200B2 (en) 2001-09-29 2012-12-11 Beiersdorf Ag Cosmetic or dermatological stick
US20040258721A1 (en) * 2001-09-29 2004-12-23 Beiersdorf Ag Cosmetic or dermatological stick
US6846846B2 (en) 2001-10-23 2005-01-25 The Trustees Of Columbia University In The City Of New York Gentle-acting skin disinfectants
US20100305211A1 (en) * 2001-10-23 2010-12-02 Shanta Modak Gentle-Acting Skin-Disinfectants and Hydroalcoholic Gel Formulations
US20030152644A1 (en) * 2001-10-23 2003-08-14 Shanta Modak Gentle-acting skin-disinfectants
US20040219227A1 (en) * 2001-10-23 2004-11-04 Shanta Modak Gentle-acting skin-disinfectants and hydroalcoholic gel formulations
US8436050B2 (en) * 2001-10-23 2013-05-07 The Trustees Of Columbia University In The City Of New York Gentle-acting skin-disinfectants and hydroalcoholic gel formulations
US8293802B2 (en) 2001-10-23 2012-10-23 The Trustees Of Columbia University Gentle-acting skin-disinfectants and hydroalcoholic gel formulations
US20040247685A1 (en) * 2001-10-23 2004-12-09 Shanta Modak Gentle-acting skin-disinfectants and hydroalcoholic gel formulations
US20040102429A1 (en) * 2002-02-07 2004-05-27 Modak Shanta M. Zinc salt compositions for the prevention of dermal and mucosal irritation
US7951840B2 (en) 2002-02-07 2011-05-31 Modak Shanta M Zinc salt compositions for the prevention of dermal and mucosal irritation
US20110117140A1 (en) * 2002-02-07 2011-05-19 Modak Shanta M Zinc Salt Compositions for the Prevention of Dermal and Mucosal Irritation
USRE45435E1 (en) 2002-02-07 2015-03-24 The Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of dermal and mucosal irritation
US20070020342A1 (en) * 2002-02-07 2007-01-25 Modak Shanta M Non-irritating compositions containing zinc salts
US7879365B2 (en) * 2002-02-07 2011-02-01 The Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of dermal and mucosal irritation
US20050048139A1 (en) * 2002-02-07 2005-03-03 Modak Shanta M. Zinc salt compositions for the prevention of dermal and mucosal irritation
US7745425B2 (en) 2002-02-07 2010-06-29 The Trustees Of Columbia University In The City Of New York Non-irritating compositions containing zinc salts
US20110152307A1 (en) * 2002-03-04 2011-06-23 Maggy Babiole Saunier Ophthalmic composition comprising ascomycin
US20120015971A1 (en) * 2002-03-04 2012-01-19 Maggy Babiole Saunier Ophthalmic composition comprising ascomycin
US20050220823A1 (en) * 2002-03-04 2005-10-06 Saunier Maggy B Ophthalmic composition comprising ascomycin
US20100113501A1 (en) * 2002-03-04 2010-05-06 Maggy Babiole Saunier Ophthalmic Composition Comprising Ascomycin
US7268102B2 (en) 2002-06-05 2007-09-11 Air Liquide Sante (International) Glyceryl ethers as preservatives for cooling lubricants
US20070197414A1 (en) * 2002-06-05 2007-08-23 Air Liquide, Sante (International) Glyceryl ethers as preservatives for cooling lubricants
US8728998B2 (en) 2002-06-05 2014-05-20 Air Liquide Sante (International) Glyceryl ethers as preservatives for cooling lubricants
US20030232729A1 (en) * 2002-06-05 2003-12-18 Wolfgang Beilfuss Glyceryl ethers as preservatives for cooling lubricants
US7846885B2 (en) 2002-06-05 2010-12-07 Air Liquide Sante (International) Glyceryl ethers as preservatives for cooling lubricants
US20040208908A1 (en) * 2003-04-16 2004-10-21 The Trustees Of Columbia University In The City Of New York Antimicrobial medical articles containing a synergistic combination of anti-infective compounds and octoxyglycerin
US9421263B2 (en) 2003-07-17 2016-08-23 The Trustees Of Columbia University In The City Of New York Antimicrobial compositions containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof
US20110070316A1 (en) * 2003-07-17 2011-03-24 Modak Shanta M Antimicrobial Compositions Containing Synergistic Combinations of Quaternary Ammonium Compounds and Essential Oils and/or Constituents Thereof
US20050019431A1 (en) * 2003-07-17 2005-01-27 Modak Shanta M. Antimicrobial compositions containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof
US7871649B2 (en) 2003-07-17 2011-01-18 The Trustees Of Columbia University In The City Of New York Antimicrobial compositions containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof
US20050129639A1 (en) * 2003-11-07 2005-06-16 Eric Quemin Makeup composition comprising an emulsion
US20070190004A1 (en) * 2004-03-18 2007-08-16 Dirk Bockmuhl Substances with a probiotic action used in deodorants
US7875653B2 (en) * 2005-10-25 2011-01-25 Beiersdorf Ag Emulsion comprising 1,2-alkanediols and polar oil components
US20070092478A1 (en) * 2005-10-25 2007-04-26 Beiersdorf Ag Emulsion comprising 1,2-alkanediols and polar oil components
US20090035390A1 (en) * 2006-01-06 2009-02-05 Modak Shanta M Compositions containing zinc salts for coating medical articles
US20100249227A1 (en) * 2006-01-06 2010-09-30 Modak Shanta M Compositions Containing Zinc Salts For Coating Medical Articles
US8207148B2 (en) 2006-01-06 2012-06-26 The Trustees Of Columbia University In The City Of New York Compositions containing zinc salts for coating medical articles
US7759327B2 (en) 2006-01-06 2010-07-20 The Trustees Of Columbia University In The City Of New York Compositions containing zinc salts for coating medical articles
US7670997B2 (en) 2006-06-08 2010-03-02 Bausch & Lomb Incorporated Ophthalmic compositions comprising a branched, glycerol monoalkyl compound and a fatty acid monoester
US20070287752A1 (en) * 2006-06-08 2007-12-13 Burke Susan E Ophthalmic Compositions Comprising A Branched, Glycerol Compound
US20070286767A1 (en) * 2006-06-08 2007-12-13 Burke Susan E Ophthalmic Compositions Comprising a Branched, Glycerol Monoalkyl Compound and a Fatty Acid Monoester
US8093193B2 (en) 2007-04-16 2012-01-10 Air Liquide Sante (International) Composition based on glycerol ether/polyol mixtures
US8058218B2 (en) * 2007-04-16 2011-11-15 Air Liquide Sante (International) Composition based on glycerol ether/polyol mixtures
US20110218250A1 (en) * 2007-04-16 2011-09-08 Air Liquide Sante (International) Composition based on glycerol ether/polyol mixtures
US20080255015A1 (en) * 2007-04-16 2008-10-16 Air Liquide Sante (International) Composition based on glycerol ether/polyol mixtures
US9981069B2 (en) 2007-06-20 2018-05-29 The Trustees Of Columbia University In The City Of New York Bio-film resistant surfaces
FR2923159A1 (fr) * 2007-11-07 2009-05-08 Oreal Utilisation d'un monoalkyle ether de glycerol a titre d'agent anti-oxydant
US20100278793A1 (en) * 2008-10-28 2010-11-04 L'oreal Treatment of greasy skin with a bacterial lystate
US9782611B2 (en) * 2008-10-28 2017-10-10 L'oreal Treatment of greasy skin with a bacterial lystate
US11730684B2 (en) * 2016-10-19 2023-08-22 Shiseido Company, Ltd. Cleansing composition

Also Published As

Publication number Publication date
CA2241894C (fr) 2004-06-22
EP0892634B1 (fr) 2002-10-09
JPH11501954A (ja) 1999-02-16
DE69716251T2 (de) 2003-02-20
ES2185050T3 (es) 2003-04-16
KR19990077273A (ko) 1999-10-25
CA2241894A1 (fr) 1998-05-28
EP0892634A1 (fr) 1999-01-27
WO1998022081A1 (fr) 1998-05-28
JP3553615B2 (ja) 2004-08-11
DE69716251D1 (de) 2002-11-14
FR2755852A1 (fr) 1998-05-22
FR2755852B1 (fr) 1998-12-24
KR100283793B1 (ko) 2002-07-18

Similar Documents

Publication Publication Date Title
US6040347A (en) Treatment of seborrhoea/cutaneous disorders with octoxyglycerol
US5352438A (en) Anti-free radical topical composition based on dismutase superoxide and a phosphonic derivative
US20070122435A1 (en) Topical dapsone for the treatment of acne
AU2002256933B8 (en) A pharmaceutical composition for the treatment of seborrhea containing 4-hydroxy-5-methoxy-4-[2-methyl-3(3-methyl-2-butenyl)-2-oxiranyl]-1-oxaspiro[2,5]octan-6-one
EP1192939A2 (en) Methods for reduction of inflammation and erythema
US20020164360A9 (en) Use of polyamino acid derivatives to treat seborrhoea and the associated skin disorders
EP1192940A1 (en) Compositions and methods for promoting clear skin using an alkanolamine
GB2216793A (en) Treatment or prophylaxis of acne, dandruff or related conditions
EP0819427B1 (fr) Utilisation de l'iodo-3 propynyl-2 butylcarbamate dans une composition cosmétique et/ou dermatologique comme actif pour le traitement de la séborrhée
JP2941241B2 (ja) 防腐系とそれを含有する化粧品用または製薬用組成物
JPH11302147A (ja) 化粧料
KR100283044B1 (ko) 지루 및/또는 여드름 치료의 유효 성분으로서 화장품 및/또는 피부과학적 조성물에 사용되는 옥트옥시글리세롤의 용도
JPH04217906A (ja) 皮膚外用剤

Legal Events

Date Code Title Description
AS Assignment

Owner name: L'OREAL, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CUPFERMAN, SYLVIE;LAUGIER, JEAN-PIERRE;REEL/FRAME:009750/0737

Effective date: 19980707

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20120321